Skip main navigation
Close Drawer MenuOpen Drawer Menu
APA Publishing Logo

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
PsychopharmacologyFull Access

FDA, FTC Warn Companies About Unapproved Opioid Therapies

Published Online:2 Feb 2018

Abstract

The FDA and the Federal Trade Commission (FTC) last week issued joint warning letters to the marketers and distributors of unapproved products that the companies claim help treat opioid addiction and withdrawal.

The 11 companies warned (and their products) are as follows: Opiate Freedom Center (Opiate Freedom 5-Pack), U4Life LLC (Mitadone), CalmSupport LLC (CalmSupport), TaperAid (TaperAid and TaperAid Complete), Medicus Holistic Alternatives LLC (Natracet), NutraCore Health Products LLC (Opiate Detox Pro), Healthy Healing LLC (Withdrawal Support), Soothedrawal Inc. (Soothedrawal), Choice Detox Center Inc. (Nofeel), GUNA Inc. (GUNA-ADDICT 1), and King Bio Inc. (AddictaPlex).

The companies were given 15 days to inform each agency of the specific actions they have taken to address their concerns. Failure to correct violations may result in law enforcement action such as seizure or injunction. ■

Back to Psychopharmacology Newsletter Table of Contents